One study found that, in patients with pancreatic cancer, there was a lack of correlation between T‐cell TIM3 immunohistochemistry (IHC) expression and patient prognosis; however, patients in this study did not receive anti‐PD‐1/PD‐L1, anti‐CTLA‐4, nor anti‐TIM‐3 treatments.18 This evidence concerns the gene HAVCR2 and pancreatic neoplasm.